Teratogenic evaluation and fetal deposition of hexabromobenzene (HBB) and hexafluorobenzene (HFB) in CD-1 mice.
HBB (hexabromobenzene) and HFB (hexafluorobenzene) were tested for their teratogenic potential in CD-1 mice. HBB and HFB were administered to pregnant mice from the 6th to the 16th day of gestation by gastric intubation. Neither HBB nor HFB were teratogenic or fetotoxic at doses up to 98.6 mg HBB/kg and 65.3 mg HFB/kg. No maternal toxicity was noted. HBB concentration in the fetuses indicated little, if any accumulation. No HFB was detected in the fetal or maternal tissues 24 hours after the last dose.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001969:Bromobenzenes / Q000633:toxicity*; D005260:Female; D005333:Fetus / Q000378:metabolism*; D005466:Fluorocarbons / Q000633:toxicity*; D005865:Gestational Age; D007668:Kidney / Q000002:abnormalities*; D008431:Maternal-Fetal Exchange; D051379:Mice; D011247:Pregnancy
D001969:Bromobenzenes; D005466:Fluorocarbons; C003005:hexafluorobenzene; C017363:hexabromobenzene